• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Genome methylation approach to search mechanisms of malignancy and new therapeutic targets in multiple myeloma

Research Project

Project/Area Number 15K09456
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Hematology
Research InstitutionSapporo Medical University

Principal Investigator

ISHIDA Tadao  札幌医科大学, 医学部, 研究員 (20305220)

Co-Investigator(Kenkyū-buntansha) 池田 博  札幌医科大学, 医学部, 助教 (60570132)
丸山 玲緒  札幌医科大学, 医学部, 研究員 (60607985)
石黒 一也  札幌医科大学, 医学部, 研究員 (90784439)
Project Period (FY) 2015-04-01 – 2018-03-31
Project Status Completed (Fiscal Year 2017)
Budget Amount *help
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords多発性骨髄腫 / エピジェネティクス / ヒストンメチル化 / メチル化 / エピジェネッティック / ゲノム
Outline of Final Research Achievements

DNA methylations and histone modifications are deeply involved in oncogenesis and inhibitors which target epigenetic modifications are used for cancer therapies. In this study, we aimed to clarify the histone methylation inhibitors which suppressed the survival of multiple myeloma (MM). As a result, we found that DOT1L inhibitors strongly repressed the proliferation of MM. Our results suggest DOT1L could be a therapeutic target in MM.

Report

(4 results)
  • 2017 Annual Research Report   Final Research Report ( PDF )
  • 2016 Research-status Report
  • 2015 Research-status Report
  • Research Products

    (7 results)

All 2018 2017 2016 2015

All Journal Article (4 results) (of which Peer Reviewed: 4 results,  Open Access: 2 results,  Acknowledgement Compliant: 1 results) Presentation (3 results)

  • [Journal Article] Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis.2016

    • Author(s)
      Shimazaki C, Fuchida S, Suzuki K, Ishida T, Imai H, Sawamura M, Takamatsu H, Abe M, Miyamoto T, Hata H, Yamada M, Ando Y
    • Journal Title

      Int J Hematol

      Volume: 103 Issue: 1 Pages: 79-85

    • DOI

      10.1007/s12185-015-1901-2

    • Related Report
      2016 Research-status Report
    • Peer Reviewed / Open Access / Acknowledgement Compliant
  • [Journal Article] A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.2016

    • Author(s)
      Watanabe T, Tobinai K, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Kashihara T, Iida S.
    • Journal Title

      Br J Haematol.

      Volume: 172 Issue: 5 Pages: 745-756

    • DOI

      10.1111/bjh.13900

    • Related Report
      2016 Research-status Report
    • Peer Reviewed
  • [Journal Article] Decrease of B-type natriuretic peptide to less than 200 pg/mL predicts longer survival in cardiac immunoglobulin light chain amyloidosis.2015

    • Author(s)
      Ishiguro K, Hayashi T, Igarashi T, Maruyama Y, Ikeda H, Ishida T, Shinomura Y.
    • Journal Title

      Int J Hematol.

      Volume: 102 Issue: 2 Pages: 200-204

    • DOI

      10.1007/s12185-015-1814-0

    • Related Report
      2015 Research-status Report
    • Peer Reviewed
  • [Journal Article] Molecular diagnostics of a single drug-resistant multiple myeloma case using targeted next-generation sequencing.2015

    • Author(s)
      Ikeda H, Ishiguro K, Igarashi T, Aoki Y, Hayashi T, Ishida T, Sasaki Y, Tokino T, Shinomura Y.
    • Journal Title

      Onco Targets Ther.

      Volume: 8 Pages: 2805-2815

    • DOI

      10.2147/ott.s86515

    • Related Report
      2015 Research-status Report
    • Peer Reviewed / Open Access
  • [Presentation] The histone methyltransferase DOT1L is a potential therapeutic target in multiple myeloma2018

    • Author(s)
      Kazuya Ishiguro, Hiroshi Kitajima, Takeshi Niinuma, Tadao Ishida, Reo Maruyama, Hiroshi Ikeda, Toshiaki Hayashi, Hajime Sasaki, Hideki Wakasugi, Koyo Nishiyama, Tetsuya Shindo, Eiichiro Yamamoto, Masahiro Kai, Yasushi Sasaki, Takashi Tokino, Hiroshi Nakase and Hiromu Suzuki
    • Organizer
      Targeting DNA Methylation and Chromatin for Cancer Therapy
    • Related Report
      2017 Annual Research Report
  • [Presentation] ヒストンメチル化酵素DOT1Lは多発性骨髄腫の治療標的となりうる2017

    • Author(s)
      石黒一也、佐々木基、若杉英樹、北嶋洋志、新沼猛、丸山玲緒、甲斐正広、池田博、石田禎夫、佐々木泰史、時野隆至、仲瀬裕志、鈴木拓
    • Organizer
      第76回日本癌学会学術総会
    • Related Report
      2017 Annual Research Report
  • [Presentation] 多発性骨髄腫に有効なヒストンメチル化阻害薬の探索2016

    • Author(s)
      石黒一也,北嶋洋志,新沼 猛,丸山玲緒,甲斐正広,西山廣陽,進藤哲哉,池田 博,石田禎夫,佐々木泰史,時野隆至,仲瀬裕志,鈴木 拓
    • Organizer
      第75回日本癌学会学術総会
    • Place of Presentation
      神奈川県横浜市、パシフィコ横浜
    • Year and Date
      2016-10-06
    • Related Report
      2016 Research-status Report

URL: 

Published: 2015-04-16   Modified: 2019-03-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi